Drug interactions
Pneumococcal vaccine 13-valent + Ublituximab
Severity: Moderate
Pneumococcal vaccine 13-valent and Ublituximab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ublituximab depletes B cells and can markedly reduce antibody responses to vaccines, including pneumococcal conjugate vaccine. Patients may remain unprotected despite vaccination.
What this interaction means in plain words
Pneumococcal vaccine 13-valent and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Pneumococcal vaccine 13-valent belongs to Miscellaneous; Ublituximab belongs to Miscellaneous.
Why it happens
Anti-CD20 B-cell depletion impairs humoral vaccine response.
What to do
Complete non-live vaccination at least 2 weeks before starting ublituximab where possible. For vaccination during therapy, expect reduced response and consider serologic testing.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Pneumococcal vaccine 13-valent and Ublituximab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Pneumococcal vaccine 13-valent
- Adalimumab + Pneumococcal vaccine 13-valent Moderate
- Alefacept + Pneumococcal vaccine 13-valent Moderate
- Anakinra + Pneumococcal vaccine 13-valent Moderate
- Anti-thymocyte + Pneumococcal vaccine 13-valent Moderate
- Antithymocyte globulin equine + Pneumococcal vaccine 13-valent Moderate
- Antithymocyte globulin rabbit + Pneumococcal vaccine 13-valent Moderate
Other interactions of Ublituximab
Frequently asked questions
Can I take Pneumococcal vaccine 13-valent with Ublituximab?
MediHelp rates the interaction as moderate. Pneumococcal vaccine 13-valent and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ublituximab depletes B cells and can markedly reduce antibody responses to vaccines, including pneumococcal conjugate vaccine. Patients may remain unprotected despite vaccination.
How serious is the interaction between Pneumococcal vaccine 13-valent and Ublituximab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Complete non-live vaccination at least 2 weeks before starting ublituximab where possible. For vaccination during therapy, expect reduced response and consider serologic testing.
What other medicines interact with Pneumococcal vaccine 13-valent?
MediHelp also lists interactions of Pneumococcal vaccine 13-valent with, for example, Adalimumab, Alefacept, Anakinra. The full list is on the Pneumococcal vaccine 13-valent page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
